Febuxostat-Theophylline Co-administration Avoiding Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with hyperuricemia requiring theophylline treatment for respiratory diseases face challenges due to drug interactions with xanthine oxidase inhibitors, leading to altered plasma concentrations and potential toxicity, necessitating frequent dosing and reduced compliance.
Innovation Solution
Administering a therapeutically effective amount of xanthine oxidoreductase inhibitors concomitantly with theophylline without causing toxicity, allowing theophylline dosing to remain within 90% to 110% of the manufacturer's recommended amount, even in the presence of these inhibitors, using specific compounds like 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If xanthine oxidase inhibitors are administered to treat hyperuricemia, then uric acid levels are reduced, but theophylline plasma concentrations are altered leading to toxicity
Solution Approach 1:
The patent introduces a specific intermediary substance (a xanthine oxidase inhibitor with distinct chemical structure) that mediates between the need to reduce uric acid and the need to maintain theophylline efficacy. This intermediary selectively inhibits xanthine oxidase without significantly affecting theophylline metabolism, thus reducing uric acid while avoiding theophylline toxicity.
Solution Approach 2:
The patent changes the chemical parameter of the xanthine oxidase inhibitor used - specifically selecting a compound with particular structural characteristics that alter its interaction profile. This parameter change (molecular structure selection) allows the drug to achieve uric acid reduction while having minimal impact on theophylline plasma concentrations, thereby avoiding toxicity.
2Reliability
If theophylline dosing is adjusted to avoid toxicity when combined with xanthine oxidase inhibitors, then safety is improved, but treatment effectiveness for respiratory diseases may be compromised
Solution Approach 1:
The selected xanthine oxidase inhibitor acts as a safe intermediary that allows theophylline to maintain its therapeutic plasma concentration range without causing toxicity. This intermediary enables the co-administration of both drugs at full therapeutic doses, ensuring both safety and effectiveness.
3Reliability
If frequent theophylline dosing is implemented to maintain effective blood levels, then treatment effectiveness is improved, but patient compliance deteriorates
Solution Approach 1:
The patent enables continuous maintenance of effective theophylline blood levels through safe co-administration with a xanthine oxidase inhibitor. This allows for sustained therapeutic action without the need for frequent dosing adjustments, improving patient compliance while maintaining treatment effectiveness for respiratory diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach avoids the need for adjusting theophylline dosing, maintaining effective plasma concentrations and reducing the risk of toxicity, thereby improving patient compliance and treatment outcomes for both hyperuricemia and respiratory diseases.
Implementation Method 1
The administration of a xanthine oxidoreductase inhibitor to a subject does not result in theophylline toxicity to the subject
Data Source
AI summary
The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.